ArticleFrontiers in neurology
Clinical and electrophysiological characteristics of myasthenia gravis patients with concomitant type 2 diabetes mellitus.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Type 2 Diabetes Mellitus (T2DM) is a common comorbidity in late-onset myasthenia gravis (MG), with pre-existing T2DM in some MG patients hinting at a possible pathogenic connection between the two disorders. This study aims to explore the clinical and neurophysiological features of MG, with a particular focus on the electrophysiological disparities between MG patients with and without T2DM. Methods: In this retrospective study, 170 MG inpatients were recruited and divided into T2DM ( Results: There were no significant differences between the two groups in terms of MG clinical classification, Quantitative MG (QMG) scores, or antibody profiles. Electrophysiologically, the T2DM group exhibited peripheral neuropathy, characterized by prolonged distal motor latencies, decreased compound muscle action potential (CMAP) amplitudes, slowed motor nerve conduction velocities, extended F-wave latencies, and sensory nerve dysfunction. In low-frequency repetitive nerve stimulation (LFRNS) of the facial nerve, the decrement pattern was predominantly "L-shaped" (minimal recovery) in T2DM patients, in contrast to the "U-shaped" pattern in non-T2DM patients. Accessory nerve LFRNS decrement showed a positive correlation with QMG score, fasting blood glucose levels, and diabetes duration. Conclusion: Patients with MG and concomitant T2DM demonstrate electrophysiological evidence of peripheral nerve impairment and a unique "L-shaped" decrement pattern on LFRNS of the facial nerve. This distinct electrophysiological phenotype likely reflects a complex interplay of metabolic derangements at the neuromuscular junction (NMJ). These results highlight the critical role of glycemic control in the management of MG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.